Article
MHC class I-related antigen-processing machinery component defects in feline mammary carcinoma.
Department of Animal Pathology, University of Turin, Grugliasco, Turin, Italy.
Translational oncology (impact factor:
3.4).
02/2012;
5(1):48-55.
pp.48-55
Source: PubMed
- Citations (1)
-
Cited In (0)
-
Article: Expression and functional analysis of human leukocyte antigen class I antigen-processing machinery in medulloblastoma.
[show abstract] [hide abstract]
ABSTRACT: Defects in the expression and/or function of the human leukocyte antigen (HLA) class I antigen-processing machinery (APM) components are found in many tumor types. These abnormalities may have a negative impact on the interactions of tumor cells with host's immune system and on the outcome of T cell-based immunotherapy. To the best of our knowledge, no information is available about APM component expression and functional characteristics in human medulloblastoma cells (Mb). Therefore, in the present study, we have initially compared the expression of APM components in Mb, an embryonal pediatric brain tumor with a poor prognosis, with that in noninfiltrating astrocytic pediatric tumors, a group of differentiated brain malignancies with favorable prognosis. LMP2, LMP7, calnexin, beta2-microglobulin-free heavy chain (HC) and beta2-microglobulin were down-regulated or undetectable in Mb lesions, but not in astrocytic tumors or normal fetal cerebellum. Two Mb cell lines (DAOI and D283) displayed similar but not superimposable defects in APM component expression as compared with primary tumors. To assess the functional implications of HLA class I APM component down-regulation in Mb cell lines, we tested their recognition by HLA class I antigen-restricted, tumor antigen (TA)-specific CTL, generated by stimulations with dendritic cells that had been transfected with Mb mRNA. The Mb cell lines were lysed by TA-specific CTL in a HLA-restricted manner. Thus, defective expression of HLA class I-related APM components in Mb cells does not impair their ability to present TA to TA-specific CTL. In conclusion, these results can contribute to optimize T cell-based immunotherapeutic strategies for Mb treatment.Cancer Research 07/2007; 67(11):5471-8. · 7.86 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed.
The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual
current impact factor.
Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence
agreement may be applicable.
Keywords
25 primary feline mammary carcinomas
animal models
animal species
APM component defects
APM components
catalytic subunits
defective processing
functional properties
healthy mammary tissues
healthy tissues
HLA class
limited extent
malignant cells
malignant transformation
MHC class
normal tissues
proteasomal cleavage specificities
reduced expression
tumor antigen-specific cytotoxic T cells
tumor cells